Trial Profile

A first-in-man clinical study of RLS-0071

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 11 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegtarazimod (Primary)
Indications Cerebral ischaemia
Focus Adverse reactions; First in man

Most Recent Events

11 Feb 2020 New trial record
06 Feb 2020 According to a ReAlta Life Sciences media release, the company expects to submit an Investigational New Drug (IND) application to FDA for hypoxic-ischemic encephalopathy later this year and expects to initiate this study in late 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com